Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.

Rahul Aggarwal,Srey Luch Sam,Vadim S. Koshkin,Eric J. Small,Felix Y. Feng,Ivan de Kouchkovsky,Daniel Kwon,Terence W. Friedlander,Hala T. Borno,Rohit Bose,Jonathan Chou,Arpita Desai,Tammy J. Rodvelt,Maya Aslam,Medini Rastogi,Lawrence Fong,Thomas A. Hope

Journal of Clinical Oncology（2021）

引用 16|浏览2

暂无评分

摘要

5053Background: Immune checkpoint inhibitors have limited single agent activity in microsatellite-stable mCRPC. 177Lu-PSMA-617 (Lu) is a PSMA-targeting radioligand therapy that has demonstrated pro...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要